Elaprase
What Elaprase is used for
Elaprase is indicated for the long-term treatment of patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Heterozygous females were not studied in the clinical trials.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Elaprase
- Active substance
- idursulfase
- Disease area
- Mucopolysaccharidosis II
- Medicine group
- Other alimentary tract and metabolism products
- ATC code
- A16AB09
- Marketing authorisation holder
- Takeda Pharmaceuticals International AG Ireland Branch
- Authorised in the EU since
- 2007
Official information
In the USA
Same active substance: Elaprase
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Elaprase used for?
Elaprase is indicated for the long-term treatment of patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Heterozygous females were not studied in the clinical trials.
What is the active substance in Elaprase?
Elaprase contains idursulfase.
Who makes Elaprase?
The EU marketing authorisation holder is Takeda Pharmaceuticals International AG Ireland Branch.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU